Hackensack Meridian Health and Eisai Inc. Form Alzheimer’s Research Collaboration Agreement
Collaboration to focus on mild cognitive impairment and other significant unmet needs
Hackensack Meridian Health and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a research collaboration agreement that initially aims to help address the significant unmet needs of people living with Alzheimer's disease, especially those experiencing the earliest stages of the disease, commonly known as mild cognitive impairment.
"We are proud to join forces with Eisai in our quest to expand early Alzheimer's disease detection and improve community services for patients, caregivers and families impacted by the disease and other types of dementia," said Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. "Hackensack Meridian Health's mission is to transform health care and this collaboration will help us to achieve our goals and benefit our communities.''
The organizations will support the expansion of early Alzheimer's disease education, detection and community services for patients and caregivers, as well as evaluate emerging tools and technological diagnostic solutions through real-world, evidence-based investigation within the Hackensack Meridian Health network. The ultimate goals of this collaboration are to further enhance care plans to support patients and their caregivers in each stage of the disease and to contribute to scalable and reproducible multi-disciplinary approaches for patient identification and management in early Alzheimer's disease.
Hackensack Meridian Health and Eisai each have unique expertise and a deep commitment to the treatment and care of Alzheimer's disease patients and their caregivers. The Center for Memory Loss and Brain Health at Hackensack University Medical Center offers integrated, high-quality screening, diagnostic and treatment services for adults living with cognitive or memory impairment caused by conditions such as Alzheimer's disease and other types of dementia.
"Both Hackensack Meridian Health and Eisai share a common goal to increase community awareness about the importance of early detection, especially in the earliest stages of cognitive loss before patients meet the criteria for a dementia diagnosis," said Manisha Parulekar, M.D., division chief, Geriatrics. "This awareness will help improve the patient and caregiver journey for those living with memory disorders."
For decades, Eisai has led dementia research and development through scientific discovery, listening to patients, caregivers and healthcare professionals, exploring solutions outside of traditional medicinal therapies, and collaboration agreements, such as the one with Hackensack Meridian Health.
Learn more about innovative geriatric care at Hackensack University Medical Center.
